Nexalis Therapeutics Limited has released a press release.
IRX211 - Targeted Pain Indication Nomination - BTcP
Filed with ASX ·
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Significant Milestone - Completion of IRX211 Phase 1 Trial
- Sep23 Quarterly Activities Report
- Sep23 Appendix 4C
- Quarterly Activities Report
- Quarterly Appendix 4C Cash Flow Report
Later from Nexalis Therapeutics
- Dec23 Appendix 4C Cash Flow Report
- Dec23 Quarterly Activities Report
- Mar24 Quarterly Activities Report
- Mar24 Appendix 4C Cash Flow Report
- Jun24 Appendix 4C Cash Flow Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics